Harrow Is Maintained at Buy by Lake Street
The Analyst Landscape: 4 Takes On Harrow
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $65
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $55
Express News | Harrow, Inc. : Craig-Hallum Raises Target Price to $65 From $45
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Harrow Relaunches FDA-approved Triesence, Shares Climb
Harrow, Inc. (HROW): A Bull Case Theory
Express News | Harrow Inc: Expansion to Create Nearly 150 New Jobs in Nashville
Harrow Announces Nashville Expansion
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $Harrow(HROW.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 52.4% and a total average return of 11.9% over
Craig-Hallum Gives a Buy Rating to Harrow Health (HROW)
Harrow Health Unveils Performance Strategy to Investors
Harrow to Present at Three Investor Conferences in September in New York
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $50
B.Riley Financial analyst Mayank Mamtani maintains $Harrow(HROW.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 27.7% and
Harrow Health's Promising Pipeline and Strategic Positioning Spur Buy Rating
Harrow Is Maintained at Buy by B. Riley Securities
Craig-Hallum Maintains Buy on Harrow, Raises Price Target to $45
Harrow Analyst Ratings